A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

Inclusion Criteria: * Persistent asthma for at least 1-year * Must use a daily asthma controller medication for at least 4 weeks prior to randomization, including an inhaled corticosteroid (ICS) with or without a long-acting beta agonist (LABA) or other adjunctive asthma therapy OR be using a leukotriene receptor antagonist (LTRA), xanthine or short acting beta agonist (SABA) as a monotherapy. * Must be able to discontinue current asthma medication * Must have a history of at least one asthma exacerbation in previous 4 to 52 weeks Exclusion Criteria: * Unstable asthma * Taking high dose ICS with or without other adjunctive therapy who have an Asthma Control Questionnaire 6 (ACQ6) total score ≥ 1.5 * Taking LTRA, xanthine or SABA monotherapy with an ACQ-6 total score \< 1.5 (controlled) * Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), or other significant, non-asthmatic, lung disease * Clinically significant abnormality, illness or disorder of any body or organ system * Significant underlying cardiovascular condition which may contraindicate use of a beta-agonist. * History of smoking greater than 10-pack years * Had an asthma exacerbation within 4 weeks of the Baseline Visit * Had more than 4 asthma exacerbations or 2 hospitalizations within 52 weeks of the randomization visit * Known or suspected hypersensitivity or intolerance to corticosteroids, beta-2 agonists, or any of the (inactive ingredients) excipients present in the medications used in this study * Require the use of chronic systemic steroids, omalizumab, or other monoclonal or polyclonal antibodies * Requires the use of beta-blockers * History of life-threatening asthma, including an asthma episode that required intubation and/or was associated with hypercapnia requiring noninvasive ventilatory support * Lactating, pregnant, or plans to become pregnant during the course of the trial